Scienture Holdings Inc (SCNX) Stock Price, Quote & News

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dih...

Industry: Pharmaceutical Retailers

Sector: Healthcare

Phone: 631) 670-6039

Website: scienture.com

Address:

20 Austin Boulevard, Commack, United States

LORAXX May. 13 at 6:56 PM

$SCNX Grab all you can. When they announce the launch of Rezenopy in June, it will go bonkers. I also believe the ER will be filled with higher than expected numbers for Arbli. GLTA

0 · Reply

Ottersberger May. 13 at 6:36 PM

$SCNX let’s go…the wall is fallen

0 · Reply

JackCampbell May. 13 at 3:28 PM

$SCNX the recent $11M non-dilutive funds clearly signal that the investor has much confidence in SCNX and this a few weeks before earnings will be released is a massive SIGN! They´ll for sure had some deeper insight on how the company is commercially progressing!

1 · Reply

Optimistgermany May. 13 at 12:43 PM

$SCNX now 16….👍👍

0 · Reply

Supremebeing24 May. 13 at 8:37 AM

$SCNX cuntish stock. Nothing to show for months on end ffs

0 · Reply

Ottersberger May. 12 at 7:58 PM

$SCNX can you 🫵🏻 pls delete you 10k Wall at 0.41 thx in advance

0 · Reply

Nakker83 May. 12 at 1:14 PM

$SCNX tuesdays are always good for news….so common

1 · Reply

Ottersberger May. 12 at 9:56 AM

$SCNX a repost on LinkedIn:

0 · Reply

OfficialStocktwitsUser May. 11 at 7:58 PM

$SCNX RSI: 50.77, MACD: 0.0038 Vol: 0.02, MA20: 0.40, MA50: 0.40 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BinaryLogic May. 9 at 11:23 AM

$SCNX [Again] The Company is scaling Arbli, further securing IP to 2041 and financing through $11M debt instrument. The $11M + $7M Cash should provide SCNX a more reasonable runway into 1H-2027 to finance Arbli commercialization (ongoing), the Rezenopy launch (Q2-2026) and the additional drugs in its pipeline. Arbli and Rezenopy address a total market of $400M (appx) and I have been estimating market penetration (total) of 15% approximately. That equates to $60M annualized sales (ultimately), or 3-4X current valuation. The Company needs to show progress in Arbli revenue scaling while concurrently launching Rezenopy - they have secured financing to 1H-2027 (appx), and I would like to hear additional progress on 104-107 in the interim. Multiplier upside on execution. SCN-104, a drug-device combination for the treatment of migraine. SCN-106, a potential biosimilar for thrombosis. SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic https://www.stocktitan.net/news/SCNX/scienture-secures-11-0-million-in-non-dilutive-debt-financing-to-an9rt1e35es8.html

1 · Reply

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

2026-05-07T03:50:06.000Z - 6 days ago

Scienture announces third patent granted for Arbli

May 6, 2026, 8:05 AM EDT - 7 days ago

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture granted 180-day extension to meet Nasdaq minimum bid price

2026-04-15T13:37:53.000Z - 4 weeks ago

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

2026-02-24T13:33:22.000Z - 2 months ago

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

2026-01-14T13:10:22.000Z - 4 months ago

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

Jan 14, 2026, 8:05 AM EST - 4 months ago

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

2025-12-22T13:15:28.000Z - 5 months ago

Scienture provides update on commercial launch of REZENOPY

Dec 22, 2025, 8:05 AM EST - 5 months ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

2025-12-10T13:20:49.000Z - 5 months ago

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

Dec 10, 2025, 8:05 AM EST - 5 months ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Dec 2, 2025, 8:05 AM EST - 5 months ago

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

2025-11-13T13:15:24.000Z - 6 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Aug 14, 2025, 9:00 AM EDT - 9 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 13, 2025, 8:05 AM EDT - 9 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 10 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

May 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Executive Leadership Transition

May 19, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

Apr 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 8, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 3, 2025, 8:26 AM EDT - 1 year ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Mar 25, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 18, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 6, 2025, 7:40 AM EST - 1 year ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Jan 21, 2025, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Dec 17, 2024, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

LORAXX May. 13 at 6:56 PM

$SCNX Grab all you can. When they announce the launch of Rezenopy in June, it will go bonkers. I also believe the ER will be filled with higher than expected numbers for Arbli. GLTA

0 · Reply

Ottersberger May. 13 at 6:36 PM

$SCNX let’s go…the wall is fallen

0 · Reply

JackCampbell May. 13 at 3:28 PM

1 · Reply

Optimistgermany May. 13 at 12:43 PM

$SCNX now 16….👍👍

0 · Reply

Supremebeing24 May. 13 at 8:37 AM

$SCNX cuntish stock. Nothing to show for months on end ffs

0 · Reply

Ottersberger May. 12 at 7:58 PM

$SCNX can you 🫵🏻 pls delete you 10k Wall at 0.41 thx in advance

0 · Reply

Nakker83 May. 12 at 1:14 PM

$SCNX tuesdays are always good for news….so common

1 · Reply

Ottersberger May. 12 at 9:56 AM

$SCNX a repost on LinkedIn:

0 · Reply

OfficialStocktwitsUser May. 11 at 7:58 PM

0 · Reply

BinaryLogic May. 9 at 11:23 AM

1 · Reply

nymostwanted May. 9 at 1:08 AM

$SCNX My main long term hold target $10 by August with hopefully some kind of news or buyout .

1 · Reply

nymostwanted May. 9 at 12:47 AM

$SCNX Waiting on a small dip to .37

0 · Reply

InvestingSpaceman May. 8 at 8:04 PM

$SCNX AW

0 · Reply

CL80 May. 8 at 6:31 PM

$SCNX a nice summary posted on T212 earlier

0 · Reply

Ottersberger May. 7 at 7:28 PM

$SCNX do we call it: accumulation?

1 · Reply

Marketmoverjoe May. 7 at 5:27 PM

$SCNX feels like it's being held down. it's now or not gonna happen

0 · Reply

Ottersberger May. 7 at 3:32 PM

$SCNX com‘on break .50 today! 11m is a good sallery

0 · Reply

khaliddaman May. 7 at 3:14 PM

$SCNX 🤑

0 · Reply

Ottersberger May. 7 at 2:49 PM

$SCNX need a .70 to break even 🥳

0 · Reply

Mo_Better May. 7 at 2:44 PM

$SCNX news in the pipeline? 🤷‍♂️

0 · Reply

LORAXX May. 7 at 2:42 PM

$SCNX Give me a repeat of Oct 23rd please...

0 · Reply

khaliddaman May. 7 at 2:40 PM

$SCNX still here, want more 🤑🤫

0 · Reply

Market Cap	16.41M
Revenue (ttm)	430,000.00
Net Income (ttm)	-41.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,653.49%
Debt to Equity Ratio	0.01

Volume	144,667
Avg Vol	3,648,012
Day's Range	N/A - N/A
Shares Out	40.63M
Stochastic %K	24%
Beta	3.32
Analysts	Strong Sell
Price Target	$1.50